

## **Referances**

**1)Ades L, Chevret S, De Botton S et al.** Outcome of acute promyelocytic leukemia treated with all transretinoic acid and chemotherapy in elderly patients: the European group experience. *Leukemia* **2005**;19:230–3.

**2)Advani R, Saba HI, Tallman MS, et al:** Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). *Blood* **93**:787-795, **2004**.

**3)Alyea EP, Kim HT, Ho V et al.** Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. *Blood* **2005**.

**4)Amadori S, Succi S, Stasi R, et al.** Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. *Leukemia*. **2005**;19:1768–1773.

**5)Appelbaum FR, Gundacker H, Head DR et al.** Age and acute myeloid leukemia. *Blood* **2006**;107 (9):3481–5.

**6)Bain, Cortes J, Thomas D, et al.** Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. *Leukemia Research* **2003**;27(10):893–7.

**7)Bennet ,Stone,Lepold, et al,** Risk of acute myelogenous leukemia and myelodysplasia following cancer treatment. *Bailliere's Clinical Haematology* **1996**;9 (1):57–85.

**8)Berneman ZN, Driessche AV, de Velde AV, et al.** Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilms'Tumor Protein WT1: A Phase I/II Trial *Blood* **2007**.

**9)Bertz H, Potthoff K, Finke J, et al** Allogenic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. *Journal of Clinical Oncology* **2003**;21(8):1480–4.

**10)Boekhorst PA, de Leeuw K, Schoester M, et al:** Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. *Blood* 82:3157-3162, **2004**.

**11)Bornhauser M, Illmer T, Schaich M, et al.** Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. *Blood*. **2007**;109:2264–2265.

**12)Boudard, Tsimberidou A, Kantarjian H, Cortes J, GarciaManero G, Faderl S. et al.** Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. *Cancer Chemother Pharmacol* **1994**.

**13)Brune ML, Rowe JM, Szer J, et al.** Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival. *Blood* **2007**.

**14)Burnett, Kell WJ, Goldstone AH, et al.** The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. *Blood* **2006**.

**15)Byrd JC, Mrozek K, Dodge RK, et al:** Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). *Blood* 100:4325-4336, **2005**.

**16)Connely SL, Rundhaugen L, Riley M, Rademaker L, Jatoi M, Tallman MS. et al.** Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. *Leukemia Res* **2007**.

**17)Chauncey TR, Rankin C, Anderson JE, et al,** A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A Southwest Oncology Group study 9617. *Leuk Res* 24:567-574, **2005**.

**18)Cheng Y, Paz K. Tandutinib, et al,**an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. *IDrugs: The Investigational Drugs Journal* **2008**; 11(1):46–56.

**19)Cheson BD, Bennett JM, Kopecky KJ,et al.** Revised recommendations of the International Working Group for Diagnosis Standardization of Response Criteria, Treatment Outcomes, and

Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *Journal of Clinical Oncology* **2003**;21(24):4642–9.

**20)Chou WC, Tang JL, Wu SJ, et al.** Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. *Leukemia*. **2007**;21:998–1004.

**21)Cimmino A, Calin GA, Fabbri M ,et al.** miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proceedings of the National Academy of Sciences of the United States of America* **2005**; 102: 13944–13949.

**22) Clavio M, Vignolo L, Albarello A, Varaldo R, Pierri I, Catania G, AM, Sessarego M, Van Lint MT, Bacigalupo A, Gobbi M, et al** Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MYFLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients *Br J Haematol* **2007**.

**23)Cortes JE, Estey E, O'Brien S ,et al.** High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. *Cancer* **2004**; 92: 7.

**24)Davis RB, Tiribelli M, Raspadori[5] Clavio M, Gatto S, R, Bacigalupo A, Gobbi M, et al.** Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose Ara-C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients. *J Exp Clin Cancer Res* **2002**;21(4):481–7.

**25)Dohner K, Schlenk RF, Habdank M, et al.** Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. *Blood*. **2005**;106:3740–3746.

**26)Estey E, de Lima M, Tibes R.** Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). *Blood* **2007**.

**27)Estey E, Thall P, Cortes JE,et al.** Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly-diagnosed AML, RAEB-t, or RAEB. *Blood* **2004**.

**28)Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E,et al.** Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/-all-trans retinoic acid +/-granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. *Blood* **2005**;93(8):2478–84.

**29)Faderl S, Gandhi V, O'Brien S, et al.** Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. *Blood* **2005**; 105.

**30)Faderl S, Verstovsek S, Cortes J, et al.** Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. *Blood* **2006**;108(1):45–51.

**31)Feldman EJ, Brandwein J, Stone R, et al.** Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. *Journal of Clinical Oncology* **2005**.

**32)Ferrara F, Viola A, Copia C, et al.** Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia. *Hematological Oncology*. **2007**.

**33)Frankel AE, Weir MA, Hall PD, Hogge DE, Rizzieri DA,et al.** Diphtheria toxin-interleukin 3 fusion protein therapy of patients with elderly or relapsed/refractory acute myeloid leukemia (AML). *J Clin Oncol*.**2006**;24:6569.

**34)Gale RE, Hills R, Kottaridis PD, et al.** No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. *Blood*. **2005**;106:3658–3665.

**35) Gerber HP, Malik AK, Solar GP, et al.** VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. *Nature* **2002**;417:954–8.

**36)Giles F, Rizzieri D, Karp J ,et al.** Cloretazine (VNP40101M),a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. *Journal of Clinical Oncology* **2007**;25(1):1–2.

**37)Giles F, Verstovsek S, Faderl S, et al.** A phase II study of loretazine (VNP40101M), a novel sulfonylhydrazine alkylating gent, in patients with very high risk relapsed acute myeloid leukemia. *Leukemia Research* **2006**;30(12):1591–5.

**38)Goldstone AH, Burnett AK, Wheatley K ,et al.** Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdome Medical Research Council AML11trial. *Blood* **2001**;98:1302–11.

**39) Gorello P, Cazzaniga G, Alberti F, et al.** Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. *Leukemia.* **2006**;20:1103–1108.

**40)Grigg AP, Reynolds J, McQuillan A, et al.** Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. *Leukemia and Lymphoma* **2005**;46(3):367–75.

**41)Grimwade D, Walker H, Harrison G, et al.** The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. *Blood* **2001**;98(5):1312–20.

**42)Grovdal M, Khan R, Aggerholm A, et al.** Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic

Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy. *Blood* **2005**;110.

**43)Hann IM, Lancet JE, Reiffers J ,et al.** A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. *Blood* **2004**; 109: 5151–5156.

**44)Hosmer DW, Lemeshow S,et al:** Applied Logistic Regression. New York, John Wiley & Sons, **2003**.

**45)Ikeda, Seow HA, et al.** Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. *Molecular Cancer Therapeutics* **1999**; 5: 969–976.

**46)Jeha S, Estey E, Kantarjian HM, et al.** Adult Acute myeloid Leukemia. *Mayo Clinic Proceedings* **2006** ;81(2)

**47)Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, S, Brookes J, Tollerfield SM, Wilson MP,et al.** A multicentre, open, noncomparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anaemia with excess of blasts in transformation. *Br J Haematol* **2001**.

**48)Johnson PR, Ryder WD, Yin JA, et al.** Validation of a model to predict survival in elderly patients with acute myeloid leukaemia. *British Journal of Haematology* **1995**;90:954–6.

**49)Jordan CT, Hoglund M, Karlsson K, et al.** Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with

cladribine. A randomized population-based phase II study. *British Journal of Haematology* **2003**.

**50)Jurcic JG, DeBlasio T, Dumont L, et al.** Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. *Clin Cancer Res* **2000**; 6: 372-380.

**51)Kassem M, Gandhi V, Cortes J, et al.** Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. *Blood* **2004**;102:2379–86.

**52)Kantarjian H, O'brien S, Cortes J, et al.** Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. *Cancer* **2006**;106(5):1090–8.

**53)Kantarjian HM, Jeha S, Gandhi V, et al.** Clofarabine: past,present, and future. *Leukemia & Lymphoma* 2007;48(10): 64. Burnett AK, Russell N, Kell JW, et al. A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy [abstract]. *Blood* **2004**;104: 248.

**54)Karp JE, Gojo I, Pili R ,et al.** Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous Leukemias:therapy with sequential 1-beta arabinofuranosyl cytosine,mitoxantrone, and bevacizumab.*Clinical Cancer Research***2004**.

**55)Karp JE, Lancet JE, Kaufmann SH ,et al.** Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.Blood **2004**;97 :3361–9.

**56)khattab&Mwafi**, spotlights on hematology, **2005**.

**57)Kolb HJ, Schmid C, Barrett AJ, et al.** Graft-versus-leukemia reactions in allogeneic chimeras. Blood **2004**;103:767–76.with leukemia.

**58)Kolitz JE, George SL, Dodge RK, et al:** Consolidation therapy by cytogenetic risk in adults with acute myeloid leukemia < 60 years in first complete remission: Results of CALGB 9621. Blood 98:688a, **2001** (abstr 2879).

**59)Lancet JE, Gojo I, Gotlib J, et al.** A phase 2 study of the farnesyl transferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood **2007**;109(4):1387–94.

**60)Leith CP, Kopecky KJ, Godwin J, et al:** Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy-A Southwest Oncology Group study. Blood 89:3323-3329, **2002**.

**61)Leopold LH, Berger MS, Cheng S, Estey E,et al.** Comparative efficacy and safety of gemtuzumab oxogamicin monotherapy in the treatment of patients with acute myeloid leukemia in first relapse. **2000**.

**62)Lange BJ, Brown P, Smith BD, et al.** Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. *Blood*. **2004**;108:3477–3483.

**63)Lowenberg B, Downing JR, Burnett A, et al** Acute Myeloid Leukemia. *New England Journal of Medicine* **2005**; 341(14):1051–62.

**64)Marcucci G, Stock W, Dai G, et al.** Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. *Journal of Clinical Oncology* **2005**;23(25):3404–11.

**65)Mayer RJ, Davis RB, Schiffer CA, et al:** Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. *N Engl J Med* 331:896-903, **2005**.

**66)Menzin J, Lang K, Earle CC ,et al.** The outcomes and costs of acute myeloid leukemia among the elderly. *Archives of Internal Medicine* **2002**;162: 1597–603.

**67)Moore J, Seiter K, Kolitz J, et al.** A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. *Leukemia Research* **2006**;30(7):777–83.

**68)Moore JO, Powell B, Velez-Garcia E, et al:** A comparison of sequential non-cross-resistant therapy or Ara-C consolidation following complete remission in adult patients < 60 years with acute myeloid leukemia: CALGB 9222. *Proc Am Soc Clin Oncol* 16:48, **2004**.

**69)National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology,et al:** Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network **2003**.

**70)Ochi T, Fujiwara H, Suemori K, et al.** Aurora-A Kinase: A Novel Target for the Immunotherapy Against Human Leukemias. Blood **2007**;110(11).

**71)Parker JE, Pagliuca A, Mijovic A, Cullis JO,et al.** Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ. Fludarabine., cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia. Br J Haematol **2004**;99(4):944–9.

**72)Parmar S, Rundhaugen LM, Boehlke L, et al.** Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leukemia Research **2004**;28(9):909–19.

**73)Paschka P, Marcucci G, Ruppert AS, et al.** Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. **2006**;24:3904.

**74)Rue M, Thomas X, Merabet F, et al.** Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study .Blood **2006**;110.

**75)Raponi M, Housseau JL, Lancet JE, et al.** Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. *Clinical Cancer Research* **2007**; 13(7):2254–60.

**76)Raza A, Jurcic JG, Roboz GJ, et al.** Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33 [abstract]. *Blood* **2007**;110(11): Abstract 159.

**77)Recher C, Beyne-Rauzy O, Demur C, et al.** Antileukemic activity of rapamycin in acute myeloid leukemia. *Blood*. **2005**;105:2527–2534.

**78)Rezvani K,Yong SMA, Mielke S, et al.** Leukemia-Associated Antigen Specific T-Cell Responses Following Combined PR1 and WT1 Peptide Vaccination in Patients with Myeloid Malignancies .*Blood* **2007**;110(11).

**79)Ries LG, Melbert D, Krapcho M, et al.** SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda,MD, November 2006 SEER data submission, posted to the SEER web site, **2007**.

**80)Roboz GJ, Giles FJ, List AF, et al.** Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. *Leukemia* **2006**.

**81)Ross DD, Wooten PJ, Sridhara R, et al:** Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. *Blood* 82:1288-1299, **2002**.

**82)Schartz, Berchtold W, Fopp M ,et al.** Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. *Lancet* **2000**;1:379–82.

**83)Sharon Manson ,Gold, Schiffer CA ,et al.** Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. *New England Journal of Medicine* **2003**;331(14):896–903.

**84)Schiffer CA, Dodge R, Larson RA,et al.** Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia. *Cancer* **2003**;80:2210–4.

**85)Scott BL, Sandmaier BM, Storer B et al.** Myeloablative vs nonmyeloablative Allogenic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. *Leukemia* **2006**.

**86)Sievers EL, Larson RA, Stadtmauer EA, et al.** Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. *J Clin Oncol* **2001**; 19: 3244-3254.

**87)Stone R, Fischer C, Paquette R, et al.** Phase 1B study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction -in newly diagnosed patients with AML *Blood*. **2005**;106:404a.

**88)Stone RM, Deangelo DJ, Klimek V, et al.** Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. *Blood*. **2004**;105:54–60.

**89)Stone RM.** Novel therapeutic agents in acute myeloid leukemia. *Experimental Hematology* **2007**;35:166–7.

**90)Streker et al, Marie JP, Cadiou M, et al.** Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. *British Journal of Haematology* **1999**;86(1):82–91.

**91)Taksin AL, Legrand O, Raffoux E ,et al.** High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. *Leukemia* **2007**;21(1):66–77.

**92)Taussig DC, Pearce DJ, Simpson C, et al.** Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. *Blood*. **2005**;106:4086–4092.

**93)Thiede C, Koch S, Creutzig E, et al.** Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). *Blood*. **2006**;107:4011–4020.

**94)Valk PJ, Lowenberg B, Burnett AK ,et al.** The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. *Blood* **2004**;106(8):2646–54.

**95)Wallen H, Gooley TA, Deeg HJ ,et al.** Ablative allogenic hematopoietic cell transplantation in adults 60 years of age and older. *Journal of Clinical Oncology* **2005**;23(15):3439–46.

**96)Wang DH, Ke XY, Wang J, et al.** Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia [abstract, article in Chinese]. *Zhonghua Yi Xue Za Zhi* **2007**;87(20): 1384-1388.

**97)Walker it, Dai G, Liu Z ,et al.** Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry. *The AAPS Journal* **2001**.

**98)Wintrobe,diagnostic cytogenetics on outcome in AML,et al:** analysis of 1,612 patients entered into the MRC AML 10 trial. **2002**.

**99)Zhong Z, Liu ZC, Li JW,et al.** The Clinical Observation on Arsenic Trioxide with ATRA in Treating Acute Promyelocytic Leukemia for Six Years [abstract]. *Blood* **2007**;110(11):